Summary
Nitrates are commonly used in the therapy of congestive heart failure (CHF). They exert beneficial hemodynamic effects by decreasing left ventricular filling pressure and systemic vascular resistance while modestly improving cardiac output. The improvement in left ventricular function caused by nitrates is the result of combined reduction in outflow resistance and mitral regurgitation, while decreased pericardial constraint and subendocardial ischemia may also contribute to the process. With continuous nitrate administration, complete arterial tolerance develops, while venous tolerance appears to be only partial. The major mechanism of tolerance is loss of vascular smooth muscle sensitivity to nitrates. An increase in total blood volume occurring during the first few hours of an acute administration may partly contribute to tolerance. The importance of reflex neurohumoral activation is controversial; although it may contribute to tolerance in CHF, its role does not appear to be major. Chronic continuous nitrate therapy in CHF improves submaximal and maximal exercise tolerance. In combination therapy with hydralazine, isosorbide dinitrate reduces mortality, although to a lesser extent than the angiotensin converting enzyme inhibitor enalapril. Intravenous or sublingual nitrates are first-line agents in the therapy of acute pulmonary edema. In severe CHF, refractory to standard medical therapy, a short course of intravenous nitroglycerin, with or without inotropic agents, can help break the vicious spiral of CHF. Because tolerance occurs without nitrate-free intervals and until an optimal schedule of administration is determined, it makes good sense to include a nightly nitrate-free interval when prescribing nitrates for CHF in order to maintain maximal benefit during the hours of activity.
Similar content being viewed by others
References
Johnson JB, Gross JF, Hale E. Effects of sublingual administration of nitroglycerin on pulmonary artery pressure in patients with failure of the left ventricle.N Engl J Med 1957;257:1114.
Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure (first of two parts).N Engl J Med 1977;297:27–31.
Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure (second of two parts).N Engl J Med 1977;297:254–258.
Cohn JN. Nitrates for congestive heart failure.Am J Cardiol 1985;56:19A-23A.
Packer M. Are nitrates effective in the treatment of chronic heart failure? Antagonist's viewpoint.Am J Cardiol 1990;66:458–461.
Dupuis J, Lalonde G, Lebeau R, Bichet D, Rouleau JL. Sustained beneficial effect of a seventy-two hour intravenous infusion of nitroglycerin in patients with severe chronic congestive heart failure.Am Heart J 1990;120:625–637.
Dupuis J, Lalonde G, Lemieux R, Rouleau JL. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: Role of increased intravascular volume, neurohumoral activation and lack of prevention with nacetylcysteine.J Am Coll Cardiol 1990;16:923–931.
Dupuis J, Lalonde G, Bichet D, Rouleau JL. Captopril does not prevent nitroglycerin tolerance in heart failure.Can J Cardiol 1990;6:281–286.
Leier CV, Bambach D, Thompson MJ, Cattaneo SM, Goldberg RJ, Unverferth DV. Central and regional hemodynamic effects of intravenous isosorbide dinitrate, nitroglycerin and nitroprusside in patients with congestive heart failure.Am J Cardiol 1981;48:1115–1123.
Sharpe N, Coxon R, Webster M, Luke R. Hemodynamic effects of intermittent transdermal nitroglycerin in chronic congestive heart failure.Am J Cardiol 1987;59:895–899.
Franciosa JA, Nordstrom LA, Cohn JN. Nitrate therapy for congestive heart failure.JAMA 1978;240:443–446.
Franciosa JA, Blank RC, Cohn JN. Nitrate effects on cardiac output and left ventricular outflow resistance in chronic congestive heart failure.Am J Med 1978;64:207–213.
Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure.N Engl J Med 1987;317:799–804.
Armstrong PW, Armstrong JA, Marks GS. Pharmacokinetic-hemodynamic studies of nitroglycerin ointment in congestive heart failure.Am J Cardiol 1980;46:670–676.
Elkayam U, Roth A, Mehra A, et al. Randomized study to evaluate the relation between oral isosorbide dinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure.Circulation 1991;84:2040–2048.
Williams DO, Bommer WJ, Miller RR, Amsterdam EA, Mason DT. Hemodynamic assessment of oral peripheral vasodilator therapy in chronic congestive heart failure: Prolonged effectiveness of isosorbide dinitrate.Am J Cardiol 1977;39:84–90.
Bayley S, Valentine H, Bennett ED. The haemodynamic responses to incremental doses of intravenous nitroglycerin in left ventricular failure.Intensive Care Med 1984;10:139–145.
Jordan RA, Seth L, Henry A, Wilen MM, Franciosa JA. Dose requirements and hemodynamic effects of transdermal nitroglycerin compared with placebo in patients with congestive heart failure.Circulation 1985;71:980–986.
Packer M, Medina N, Yushak M, Lee WH. Hemodynamic factors limiting the response to transdermal nitroglycerin in severe chronic congestive heart failure.Am J Cardiol 1986;57:260–267.
Rajfer SI, Demma FJ, Goldberg LI. Sustained beneficial hemodynamic responses to large doses of transdermal nitroglycerin in congestive heart failure and comparison with intravenous nitroglycerin.Am J Cardiol 1984;54:120–125.
Packer M. Mechanisms of nitrate action in patients with severe left ventricular failure: Conceptual problems with the theory of venosequestration.Am Heart J 1985;110:259–264.
Keren G, Bier A, Strom JA, Laniado S, Sonnenblick EH, Lejemtel TH. Dynamic of mitral regurgitation during nitroglycerin therapy: A Doppler echocardiographic study.Am Heart J 1986;112:517–525.
Keren G, Katz S, Strom J, Sonnenblick E, LeJemtel TH. Dynamic mitral regurgitation. An important determinant of the hemodynamic response to load alterations and inotropic therapy in severe heart failure.Circulation 1989;80:306–313.
Cohn JN. Role of nitrates in congestive heart failure.Am J Cardiol 1987;60:39H-43H.
Schneider AJ, Teule GJ, Groeneveld AB, Nauta J, Luth WJ. The immediate effect of nitroglycerin on total body volume distribution in patients with congestive heart failure: A non-invasive study.Eur Heart J 1987;8:1119–1125.
Smith ER, Smiseth OA, Kingma I, Manyari D, Belenkie I, Tyberg J. Mechanism of action of nitrates. Role of changes in venous capacitance and in the left ventricular diastolic pressure-volume relation.Am J Med 1984;76:14–21.
Winbury MM. Redistribution of left ventricular blood flow produced by nitroglycerin.Circ. Res 1971;28:140–147.
Gorman MW, Sparks HV. Nitroglycerin causes vasodilation within ischemic myocardium.Cardiovasc Res 1980;14:515.
Greenberg H, Dwyer EM, Jameson AG, et al. Effects of nitroglycerin on the major determinants of myocardial oxygen consumption. An angiographic and hemodynamic assessment.Am J Cardiol 1975;36:426–432.
Elkayam U, Kulick D, McIntosh N, Roth A, Hsueh W, Rahimtoola SH. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure.Circulation 1987;76:577–584.
Olivari MI, Carlyle PF, Levine TB, Cohn JN. Hemodynamic and hormonal response to transdermal nitroglycerin in normal subjects and in patients with congestive heart failure.J Am Coll Cardiol 1983;2:872–878.
Sharpe N, Coxon R. Nitroglycerin in a transdermal therapeutic system in chronic heart failure.J Cardiovasc Pharmacol 1984;6:76–82.
Franciosa JA, Cohn JN. Effect of isosorbide dinitrate on response to submaximal and maximal exercise in patients with congestive heart failure.Am J Cardiol 1979;43:1009–1014.
Leier CV, Huss P, Magouin RD, Unverferth DV. Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure.Circulation 1983;67:817–822.
Franciosa JA, Cohn JN. Sustained hemodynamic effects without tolerance during long term isosorbide dinitrate treatment of chronic left ventricular failure.Am J Cardiol 1980;45:648–654.
Jordan RA, Seth L, Casebolt P, Hayes MJ, Wilen MM, Franciosa J. Rapidly developing tolerance to transdermal nitroglycerin in congestive heart failure.Ann Intern Med 1986;104:295–298.
Münzel T, Holtz J, Mülsch A, Stewart DJ, Bassenge E. Nitrate tolerance in epicardial arteries O2 in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist.Circulation 1989;79:188–197.
Unger P, Leone A, Staroukine M, Degre S, Berkenboom G. Hemodynamic response to molsidomine in patients with ischemic cardiomyopathy tolerant to isosorbide dinitrate.J Cardiovasc Pharmacol 1991;18:888–894.
Parker JD, Farrel B, Parker AC, Cahanim MA, Parker JO. Neurohumoral responses and the hemodynamic adaptation to nitrates (abstr).Circulation 1990;82(Suppl III):III200.
Elkayam U, Roth A, Henriquez B, Weber L, Tonnemacher D, Rahimtoola SH. Hemodynamic and hormonal effects of high-dose transdermal nitroglycerin in patients with chronic congestive heart failure.Am J Cardiol 1985;56:555–559.
Derchi G, Dupuis J, de Champlain J, Rouleau JL. Paradoxical decrease in circulating neuropeptide-Y levels during mild orthostatic stress in normal and patients with congestive heart failure.Eur Heart J 1992;14:34–39.
Dakak N, Makhoul N, Fugelman MY, et al. Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease.Am J Cardiol 1990;66:608–613.
Wilson JR, Ferraro N. Effect of isosorbide dinitrate on submaximal exercise capacity of patients with chronic left ventricular failure.Chest 1982;82:701–704.
Creager MA, Massie BM, Faxon DP, et al. Acute and long term effect of enalapril on the cardiovascular response to exercise in patients with congestive heart failure.J Am Coll Cardiol 1985;6:163–173.
Packer M, Medina N, Yushak M. Comparative hemodynamic and clinical effect of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy.Am J Cardiol 1986;57:1323–1327.
Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality of chronic congestive heart failure.N Engl J Med 1986;314:1547–1552.
Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.N Engl J Med 1991;325:303–310.
Bussmann WD, Schupp D. Effect of sublingual nitroglycerin in emergency treatment of severe pulmonary edema.Am J Cardiol 1978;41:931–936.
Loeb H, Ostrenga JP, Gaul W, et al. Beneficial effects of dopamine combined with intravenous nitroglycerin on hemodynamics in patients with severe left ventricular failure.Circulation 1983;68:813–820.
Awan NA, Evenson NK, Needham KE, Beattie JM, Mason DT. Effect of combined nitroglycerin and dobutamine infusion in left ventricular dysfunction.Am Heart J 1983;106:35–40.
Gagnon RM, Fortin L, Boucher R, et al. Combined hemodynamic effects of dobutamine and IV nitroglycerin in congestive heart failure.Chest 1980;78:694–698.
Kubo HS, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure.Circulation 1991;84:1589–1596.
Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change.Circulation 1992;85:510–517.
Treasure CB, Alexander RW. The dysfunctional endothelium in heart failure.J Am Coll Cardiol 1993;22(SupplA):129A-134A.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dupuis, J. Nitrates in congestive heart failure. Cardiovasc Drug Ther 8, 501–507 (1994). https://doi.org/10.1007/BF00877928
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00877928